A Chart Review to Evaluate the Safety and Efficacy of MeRT on Subjects With ASD

Wave Neuroscience

Status: Completed

Conditions: Autistic Disorder

Treatments: Other: MeRT Efficacy Chart Review

Study type: Observational

Funder types: Industry

Identifiers

NCT02758496

MeRT-016

Details and patient eligibility

About

The purpose of this study is to evaluate the safety and efficacy of Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) on subjects with Autism Spectrum Disorder (ASD).

Full description

This is a retrospective chart review of 200 consecutive charts of subjects ages 2-20 years old seen at the Brain Treatment Center between 2010 and 2015. The review is designed to evaluate the safety and efficacy of Magnetic Electroencephalogram/Electrocardiogram(EEG/ECG)-Guided Resonance Therapy (MeRT) on subjects with Autism Spectrum Disorder (ASD).

Enrollment: 141 patients

Sex: All

Ages: 2 to 20 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Must have completed a baseline EEG at the Brain Treatment Center (BTC)

2. Age between 2 and 20 years old at initial visit

3. Must have a diagnosis of ASD according to the prevailing standard at that time (i.e., Diagnostic and Statistical Manual-IV (DSM-IV)) (ASD Group only)

4. Must have received Magnetic EEG/ECG-Guided Resonance Therapy (MeRT) for more than (5) sessions (ASD Group only)

   Exclusion Criteria:

5. Clinically significant abnormality or clinically significant unstable medical condition during treatment that in the Investigator's judgment may have may limited interpretation of the results.

Trial design

141 participants in 2 patient groups

ASD Subjects

Description:

Approximately two hundred (200) male and female subjects of any ethnic background between the ages of 2-20 years old seen at the Brain Treatment Center (BTC) between 2010 and 2015.

Treatment:

Other: MeRT Efficacy Chart Review

Healthy Controls

Description:

Twenty (20) male and female subjects of any ethnic background between the ages of 2-20 years old with 'neurotypical' EEGs will be selected for comparison to the ASD group

Treatment:

Other: MeRT Efficacy Chart Review